Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy

European Journal of Pharmacology

Volumn 553, Issue 1-3, 2006, Pages 89-98

  Rawls, Scott M ^a   Tallarida, Ronald J ^b   Zisk, Jacob ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agmatine; Cannabinoid; CB1; Hypothermia; Imidazoline; WIN 55212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AGMATINE; IDAZOXAN; IMIDAZOLINE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HYPOTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY;

ADRENERGIC ALPHA-ANTAGONISTS; AGMATINE; ANIMALS; BODY TEMPERATURE; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYPOTHERMIA; IDAZOXAN; INJECTIONS, INTRAVENTRICULAR; MALE; MORPHOLINES; NAPHTHALENES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; YOHIMBINE;

EID: 33751195078     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.038     Document Type: Article

References (53)

1. Aricioglu F., and Regunathan S. Agmatine attenuates stress-and lipopolysaccharide-induced fever in rats. Physiol. Behav. 85 (2005) 370-375
2. Aricioglu-Kartal F., and Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci. 61 (1997) 1775-1781
3. Bhattacharya S.K. delta-9-tetrahydrocannabinol (THC) increases brain prostaglandins in the rat. Psychopharmacology (Berlin) 90 (1986) 499-502
4. 2-adrenoceptor or mu-opioid receptor mechanisms. Eur. J. Pharmacol. 331 (1997) 133-138
5. Burstein S. Eicosanoids as mediators of cannabinoid action. In: Murphy L., and Bartke A. (Eds). Marijuana/Cannabinoids: Neurobiology and Neurophysiology (1992), CRC Press, Boca Raton, FL 73-91
6. Cambridge N., and Robinson E.S. Effect of BU98008, an imidazoline1-binding site ligand, on body temperature in mice. Eur. J. Pharmacol. 519 (2005) 86-90
7. Compton D.R., Gold L.H., Ward S.J., Balster R.L., and Martin B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263 (1992) 1118-1126
8. Ernsberger P. Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1-imidazoline receptors. J. Auton. Nerv. Syst. 72 (1998) 147-154
9. Fairbanks C.A., Schreiber K.L., Brewer K.L., Yu C.G., Stone L.S., Kitto K.F., Nguyen H.O., Grocholski B.M., Shoeman D.W., Kehl L.J., Regunathan S., Reis D.J., Yezierski R.P., and Wilcox G.L. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10584-10589
10. Feng Y., LeBlanc M.H., and Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci. Lett. 390 (2005) 129-133
11. Gilad G.M., Salame K., Rabey J.M., and Gilad V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. 58 (1996) PL41-PL46
12. Glavin G.B., Carlisle M.A., and Smyth D.D. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats. J. Pharmacol. Exp. Ther. 274 (1995) 741-744
13. Halaris A., and Piletz J.E. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann. N.Y. Acad. Sci. 1009 (2003) 1-20
14. Head G.A., and Mayorov D.N. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc. Hematol. Agents. Med. Chem. 4 (2006) 17-32
15. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., and Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 Suppl 1 (2004) 345-358
16. Kalra S.P., Pearson E., Sahu A., and Kalra P.S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci. Lett. 194 (1995) 165-168
17. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296 (1996) 17-22
18. Kuzirian A., Meyhöfer E., Hill L., Neary J.T., and Alkon D.L. Autoradiographic measurement of tritiated agmatine as an indicator of physiologic activity in hermissenda visual and vestibular neurons. J. Neurocytol. 15 (1986) 629-643
19. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
20. Li Y.F., Gong Z.H., Cao J.B., Wang H.L., Luo Z.P., and Li J. Antidepressant-like effect of agmatine and its possible mechanism. Eur. J. Pharmacol. 469 (2003) 81-88
21. Loring R.H. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br. J. Pharmacol. 99 (1990) 207-211
22. Lumb P.J., McMahon Z., Chik G., and Wierzbicki A.S. Effect of moxonidine on lipid subfractions in patients with hypertension. Int. J. Clin. Pract. 58 (2004) 465-468
23. Martin B.R. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sci. 77 (2005) 1543-1558
24. Mukaddam-Daher S., and Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Braz. J. Med. Biol. Res. 37 (2004) 1239-1245
25. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
26. Nguyen H.O., Goracke-Postle C.J., Kaminski L.L., Overland A.C., Morgan A.D., and Fairbanks C.A. Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine). Ann. N.Y. Acad. Sci. 1009 (2003) 82-105
27. Onal A., Delen Y., Ulker S., and Soykan N. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci. 73 (2003) 413-428
28. Ovadia H., Wohlman A., Mechoulam R., and Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 34 (1995) 175-180
29. Ozawa H., Chen C.S., Watanabe H., and Uematsu T. Effect of clonidine on blood pressure, heart rate and body temperature in conscious rats. Jpn. J. Pharmacol. 27 (1977) 47-54
30. Pertwee R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 168 (2005) 1-51
31. Pertwee R.G., Hedley D., McQueen A.S., and Gentleman S.M. The hypothermic response of mice to delta-9-tetrahydrocannabinol is enhanced by chlorpromazine, thioxanthenes, alpha-adrenoceptor antagonists and pentolinium but not by SCH 23390 or sulpiride. Neuropharmacology 27 (1988) 149-155
32. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., and Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51 (1998) 391-402
33. Piletz J.E., Chikkala D.N., and Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenoceptors. J. Pharmacol. Exp. Ther. 272 (1995) 581-587
34. Raasch W., Regunathan S., Li G., and Reis D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. 56 (1995) 2319-2330
35. 1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4, 5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo [3, 2, 1ij]quinolin-6-one]-induced hypothermia. J. Pharmacol. Exp. Ther. 301 (2002) 963-968
36. Rawls S.M., Tallarida R.J., Gray A.M., Geller E.B., and Adler M.W. l-NAME (N omega-nitro-l-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J. Pharmacol. Exp. Ther. 308 (2004) 780-786
37. Regunathan S., Feinstein D.L., Raasch W., and Reis D. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. NeuroReport 6 (1995) 1897-1900
38. Reis D.J., and Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol. Sci. 21 (2000) 187-193
39. Reis D.J., Yang X.C., and Milner T.A. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neurosci. Lett. 250 (1998) 185-188
40. Roerig S.C. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann. N.Y. Acad. Sci. 1009 (2003) 116-126
41. Romanovsky A.A., Almeida M.C., Aronoff D.M., Ivanov A.I., Konsman J.P., Steiner A.A., and Turek V.F. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci. 10 (2005) 2193-2216
42. Ruggiero D.A., Regunathan S., Wang H., Milner T.A., and Reis D.J. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. 780 (1998) 270-293
43. Ruiz-Durantez E., Ruiz-Ortega J.A., Pineda J., and Ugedo L. Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br. J. Pharmacol. 135 (2002) 1152-1158
44. SAMSHA. National Household Survey on Drug Abuse (2000), Author, Rockville, MD
45. Sanchez-Blazquez P., Boronat M.A., Olmos G., Garcia-Sevilla J.A., and Garzon J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol. 130 (2000) 146-152
46. Sastre M., Regunathan S., Galea E., and Reis D.J. Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J. Neurochem. 67 (1996) 1761-1765
47. Sastre M., Regunathan S., and Reis D.J. Uptake of agmatine into rat brain synaptosomes: possible role of cation channels. J. Neurochem. 69 (1997) 2421-2426
48. Schwartz D., Peterson O.W., Mendonca M., Satriano J., Lortie M., and Blantz R.C. Agmatine effects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am. J. Physiol. 272 (1997) F597-F601
49. Su R.B., Li J., Gao K., Pei G., and Qin B.Y. Influence of idazoxan on analgesia, tolerance, and physical dependence of morphine in mice and rats in vivo. Acta Pharmacol. Sin. 21 (2000) 1011-1015
50. Su R.B., Li J., and Qin B.Y. A biphasic opioid function modulator: agmatine. Acta Pharmacol. Sin. 24 (2003) 631-636
51. Su R.B., Wei X.L., Zheng J.Q., Liu Y., Lu X.Q., and Li J. Anticonvulsive effect of agmatine in mice. Pharmacol. Biochem. Behav. 77 (2004) 345-349
52. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 298 (2001) 865-872
53. Zomkowski A.D., Santos A.R., and Rodrigues A.L. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci. Lett. 381 (2005) 279-283